Pneumococcal conjugate second or third-dose vaccines (PCVc) in Iran
Iran: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 54.0% in 2025. ◆ Volatile
Latest (2025)
54.0%
World rank
153rd
of 194 countries
All-time high
54.0%
in 2025
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Iran, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Iran recorded 54.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Iran peaked at 54.0% in 2025 and was at its lowest, 0.0%, in 2008.
That places Iran 153rd out of 194 countries with data for 2025, putting it in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Iran, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 0.0% | — |
| 2019 | 0.0% | — |
| 2020 | 0.0% | — |
| 2021 | 0.0% | — |
| 2022 | 0.0% | — |
| 2023 | 0.0% | — |
| 2024 | 0.0% | — |
| 2025 | 54.0% | — |
Iran compared with similar countries
- Iran's 54.0% is below the median for upper middle income countries, which is 76.0%, 71% of the median. (57 countries reporting)
- Iran's 54.0% is below the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 59% of the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 0.0% | 0.0% | 0.0% | 10 |
| 2020s | 9.0% | 0.0% | 54.0% | 6 |
Countries ranked near Iran
- 151 Madagascar 56.0% compare
- 152 Slovenia 55.0% compare
- 153 Angola 54.0% compare
- 155 Azerbaijan 52.0% compare
- 156 Kazakhstan 49.0% compare
- 156 Chad 49.0% compare
More health data for Iran
- Un projection of annual infant deaths, annual growth rate -1.38 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.5627 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,361 deaths per 1,000 people (2090)
- Number of infants who die before age 1 1,070 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -1.88 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0311 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.95 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Iran?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Iran was 54.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Iran?
- The highest recorded value was 54.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Iran?
- The lowest recorded value was 0.0% in 2008.
- How does Iran rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iran ranks 153rd out of 194 countries with data for 2025.
- Where does this Iran data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).